Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool March 14, 2011 Brian Orelli	This Deal Is No Dog Eli Lilly picks up Johnson & Johnson's European animal-health business.
The Motley Fool September 22, 2009 Brian Orelli	Pfizer and Wyeth Put the Horse Before the Cart The pharmas' animal-business divestiture brings them one step closer to unity.
The Motley Fool July 30, 2009 Brian Orelli	Merck, Sanofi, and Schering's Love Triangle Perhaps the most complicated deal of the year.
The Motley Fool March 8, 2010 Brian Orelli	Pfizer Still Dealing With Antitrust Issues The pharma giant sells off some more animal health assets.
The Motley Fool June 4, 2009 Brian Orelli	MegaMergers Going to the Dogs It looks like Merck isn't sure it'll be able to get its acquisition of Schering-Plough past regulators without doing a little trimming.
The Motley Fool September 1, 2009 Brian Orelli	Merck to Bride: Leave the Jewelry at Home The new Merck will look a lot like the old Merck at the top, even though about 40% of Schering's senior leaders will be headed to the new company.
The Motley Fool December 30, 2010 Brian Orelli	Pfizer Diagnoses Fido, Too The drugmaker's animal health division purchases Synbiotics.
The Motley Fool July 8, 2011 Brian Orelli	Half a Breakup Is Better Than No Breakup at All Pfizer keeps two divisions and puts two on the chopping block.
The Motley Fool November 4, 2009 Brian Orelli	An Ode to Schering-Plough Mergers and acquisitions in the pharmaceutical industry are cataloged in a poem.
The Motley Fool September 29, 2011 Brian Orelli	Joint-Venture Acid Reflux Merck ditches its joint venture with Johnson & Johnson.
The Motley Fool November 30, 2009 Brian Orelli	Making Money More Efficiently Drug companies shape up, and it shows in their margins.
The Motley Fool October 23, 2009 Brian Orelli	Merck-Schering Doesn't Look So Good Revenue is stagnant; let's hope that pipeline pans out.
The Motley Fool December 22, 2009 Brian Orelli	This Acquisition Is Icy Hot Expensive price, but Chattem may still be a good buy for sanofi-aventis.
The Motley Fool April 15, 2011 Brian Orelli	Dark Clouds Lift Over Pharma Dispute The case of who bought whom in the Merck -Schering-Plough deal has ended in a draw.
The Motley Fool October 27, 2009 Brian Orelli	Pfizer's and Merck's Loss Is These Companies' Gain Are Pfizer and Merck too busy integrating now to take advantage of additional acquisitions?
The Motley Fool February 16, 2010 Brian Orelli	Merck Gets a Pass, for Now Its first quarter looks promising, but not as good as could be hoped.
The Motley Fool November 5, 2009 Brian Orelli	Slow Down There, Merck Merck CEO Richard Clark says his company is looking to do more deals than ever, perhaps "even try to double" the current rate of 50 per year.
The Motley Fool January 12, 2011 Brian Orelli	Drugmaker Math: 4 Halves Beat 2 Wholes Eli Lilly and Boehringer Ingelheim hook up.
The Motley Fool September 15, 2011 Brian Orelli	Stop Worrying About Pfizer's Breakup Sometimes you just have to trust management.
The Motley Fool March 9, 2009 Brian Orelli	Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth.
The Motley Fool February 29, 2008 Brian Orelli	2007 Pharma Roundup How did big pharma do in 2007? With the drug sector earnings season winding down, now seems like a good time to take a look at how they fared and, more importantly, where they're headed.
The Motley Fool March 24, 2009 Robert Steyer	Drugmakers Diversify -- Again Merck and Pfizer choose businesses they once eschewed.
The Motley Fool July 24, 2006 Stephen D. Simpson	Can Schering-Plough Continue to Shine? Cost-cutting and cholesterol drug sales continue apace, but is the company vulnerable? Investors, take note.
The Motley Fool July 21, 2009 Brian Orelli	Merck and Schering: A Less Ugly Bride and Groom Merck and Schering-Plough are up today on "better than expected" earnings, but the bride and groom don't look all that great heading into the wedding.
The Motley Fool December 16, 2008 Brian Orelli	Pfizer Keeps the Change For the first time in decades, investors won't get a dividend increase.
The Motley Fool December 12, 2008 Brian Orelli	A Long-Term Play for Your Port Long-term prospects look better than the near term ones for Eli Lilly and its investors.
The Motley Fool May 21, 2009 Brian Orelli	Not So Fast, Schering ... er, Merck ... er, Whoever You Are Merck got cute with its acquisition of Schering-Plough by setting up the merger so that Schering is technically merging with Merck and then changing its name to Merck. That seemingly schizophrenic move had a purpose.
The Motley Fool March 2, 2010 Brian Orelli	Merck: Poised for Growth and Eager to Go Merck needs its new, stronger, post-acquisition pipeline to pay off.
The Motley Fool December 24, 2007 Rick Aristotle Munarriz	4 Stocks That Took a Hike These stocks recently raised their dividends: Pfizer... Eli Lilly... Moody's... Waste Management...
The Motley Fool March 18, 2009 Brian Orelli	Merck Pummels Pfizer One of these acquisitions is not like the other.
The Motley Fool May 12, 2009 Brian Orelli	Another Reason to Hate Big Pharma's M&A As we get closer to Pfizer and Merck wrapping up their deals, it looks like a new group is voicing their displeasure: external partners.
The Motley Fool January 27, 2004 Jeff Hwang	Merck in the Balance These are troubled times for Merck. Restructuring charges, Zocor sales woes, and a new distribution program hamper earnings.
The Motley Fool March 23, 2011 Brian Orelli	Eli Lilly: Great Plan, Poor Execution Eli Lilly shuns large mergers, but hasn't produced drugs on its own.
The Motley Fool November 30, 2011 Brian Orelli	3 Things More Important to Pfizer Than Losing Lipitor It's not like we didn't see it coming.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Rebuttal There's a reason why Merck's stock is cheap: weak pipeline, weak prospects.
The Motley Fool December 30, 2010 Brian Orelli	2011 Drugmaker M&A Targets What Big Pharma M&A deals will 2011 hold? Most likely, more small deals, and perhaps Sanofi will finally offer a reasonable price for Genzyme. Let's take a look at some of the companies that might be walking down the aisle next year.
The Motley Fool November 25, 2009 Brian Orelli	A Schizophrenic Move by Merck? Issue $29 billion in shares, buy back $3 billion. Say what? Merck increased its share count by almost 45% to pay for the acquisition of Schering-Plough. Now it's planning to buy some of that stock back.
BusinessWeek April 16, 2007 Arlene Weintraub	Big Pharma's Animal Spirits Sales of medicine for pets and livestock are giving drugmakers a welcome boost.
The Motley Fool February 11, 2010 Brian Orelli	A Turnaround Year, But Not in a Good Way 2009 was a solid year for sanofi-aventis thanks to a boost from sales of swine flu vaccine and some help from the exchange rate. But 2010? Not so solid.
The Motley Fool February 9, 2009 Robert Steyer	Just Say No to Drug Company Mergers There are some reasons to make a big-pharma deal. But there are as many, if not more, reasons to let these companies pursue smaller deals and collaborations rather than become just another part of a hyphenated corporate name.
The Motley Fool January 28, 2011 Brian Orelli	Avoid This Falling Knife for Now 2011 could be just the start of a long slide for Lilly. And 2012 will see difficult year-over-year comparison.
The Motley Fool December 10, 2009 Brian Orelli	A Tale of Two Lillys It was the best of times, it was the worst of times. Dickens could have been talking about Eli Lilly which has a tale of two cities all on its own.
The Motley Fool October 21, 2004 Roger Nusbaum	Pictures of Lilly Eli Lilly's numbers get lost in the wake of Merck and Pfizer. While the market waits for drug stocks to recover, investors can collect Lilly's 2.5%, safe, dividend.
The Motley Fool October 8, 2008 Brian Orelli	Lilly Gets Off Easy The company settles marketing issues over Zyprexa with 32 states.
The Motley Fool October 21, 2010 Brian Orelli	Genzyme: Nice Quarter, Still Too Expensive After its train wreck of manufacturing problems, Genzyme seems like it's getting the cars back on track.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist?
The Motley Fool May 5, 2010 Brian Orelli	Doubled Revenue, but Not High Growth An acquisition and some rearrangements make Merck's revenue line sound better than it is.
The Motley Fool July 8, 2010 Brian Orelli	Surprise Us in a Good Way, Merck Keeping up productivity during plant closures won't be easy.
The Motley Fool July 23, 2009 Brian Orelli	The Slowly Wilting Lilly Nothing can save this drug company.
The Motley Fool September 30, 2009 Brian Orelli	Bigger Size, Lower Returns History is not on Merck and Schering's side.